| 7.09 1.54 (27.75%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.37 |
1-year : | 9.78 |
| Resists | First : | 7.17 |
Second : | 8.37 |
| Pivot price | 5.31 |
|||
| Supports | First : | 5.57 |
Second : | 4.59 |
| MAs | MA(5) : | 5.81 |
MA(20) : | 5.29 |
| MA(100) : | 4.68 |
MA(250) : | 5.21 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 87.2 |
D(3) : | 83.9 |
| RSI | RSI(14): 78.5 |
|||
| 52-week | High : | 9.23 | Low : | 3.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SGHT ] has closed It is unclear right now based on current values. 89.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.18 - 7.21 | 7.21 - 7.23 |
| Low: | 5.72 - 5.75 | 5.75 - 5.78 |
| Close: | 7.03 - 7.09 | 7.09 - 7.14 |
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Thu, 06 Aug 2026
Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates - Kalkine
Thu, 06 Aug 2026
Sight Sciences Q2 Earnings Call Highlights - TradingView
Wed, 05 Aug 2026
Sight Sciences wins FDA clearance for Omni Surgical System - massdevice.com
Wed, 05 Aug 2026
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 05 Aug 2026
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Wed, 05 Aug 2026
Aetna covers Sight Sciences glaucoma devices for commercial plans By Investing.com - Investing.com Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 54 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 19.9 (%) |
| Held by Institutions | 53.5 (%) |
| Shares Short | 830 (K) |
| Shares Short P.Month | 805 (K) |
| EPS | -0.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | -46.9 % |
| Operating Margin | -35.6 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -56.7 % |
| Qtrly Rev. Growth | 12.5 % |
| Gross Profit (p.s.) | 1.25 |
| Sales Per Share | 1.46 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -10.13 |
| PEG Ratio | 0 |
| Price to Book value | 7.09 |
| Price to Sales | 4.84 |
| Price to Cash Flow | -15.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|